{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:16:07Z","timestamp":1740122167228,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T00:00:00Z","timestamp":1474070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T00:00:00Z","timestamp":1474070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 DK007533-29","T32 DK007533-29"],"award-info":[{"award-number":["T32 DK007533-29","T32 DK007533-29"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s10620-016-4302-3","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T04:52:55Z","timestamp":1474087975000},"page":"3261-3269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery"],"prefix":"10.1007","volume":"61","author":[{"given":"Edward L.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel W.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Carrellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua R.","family":"Korzenik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,17]]},"reference":[{"key":"4302_CR1","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"4302_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"4302_CR3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"4302_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u2013332.","journal-title":"Gastroenterology"},{"key":"4302_CR5","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20131239.","journal-title":"Gut"},{"key":"4302_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ. Adalimumab induction therapy for crohn disease previously treated with infliximab. Ann Intern Med. 2007;146:829.","journal-title":"Ann Intern Med"},{"key":"4302_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"4302_CR8","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u20132476.","journal-title":"N Engl J Med"},{"key":"4302_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","volume":"60","author":"W Reinisch","year":"2011","unstructured":"Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780\u2013787.","journal-title":"Gut"},{"key":"4302_CR10","doi-asserted-by":"publisher","first-page":"257.e3","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257.e3\u2013265.e3.","journal-title":"Gastroenterology"},{"key":"4302_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"J-F Colombel","year":"2010","unstructured":"Colombel J-F, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u20131395.","journal-title":"N Engl J Med"},{"key":"4302_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/MIB.0000000000000115","volume":"20","author":"A Armuzzi","year":"2014","unstructured":"Armuzzi A, Pugliese D, Danese S, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2014;20:1368\u20131374.","journal-title":"Inflamm Bowel Dis"},{"key":"4302_CR13","doi-asserted-by":"publisher","first-page":"392.e3","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392.e3\u2013400.e3.","journal-title":"Gastroenterology"},{"key":"4302_CR14","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.3748\/wjg.v19.i17.2676","volume":"19","author":"K Ishida","year":"2013","unstructured":"Ishida K, Inoue T, Fujiwara K, et al. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn\u2019s disease patients. World J Gastroenterol. 2013;19:2676\u20132682.","journal-title":"World J Gastroenterol"},{"key":"4302_CR15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/gut.2010.212712","volume":"59","author":"H Sokol","year":"2010","unstructured":"Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59:1363\u20131368.","journal-title":"Gut"},{"key":"4302_CR16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cgh.2013.06.004","volume":"11","author":"NS Abraham","year":"2013","unstructured":"Abraham NS, Richardson P, Castillo D, Kane SV. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:1281\u20131287.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4302_CR17","first-page":"63.e5","volume":"142","author":"E Louis","year":"2012","unstructured":"Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63.e5\u201370.e5. quiz e31.","journal-title":"Gastroenterology"},{"key":"4302_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","volume":"148","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis. Gastroenterology. 2015;148:344\u2013354.","journal-title":"Gastroenterology"},{"key":"4302_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cgh.2010.04.023","volume":"8","author":"GY Melmed","year":"2010","unstructured":"Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn\u2019s disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655\u2013659.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4302_CR20","first-page":"2233.e1-2","volume":"13","author":"JL Jones","year":"2015","unstructured":"Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-TNF therapy for Crohn\u2019s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13:2233.e1-2\u20132240.e1-2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4302_CR21","first-page":"681.e1","volume":"146","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease. Gastroenterology. 2014;146:681.e1\u2013688.e1.","journal-title":"Gastroenterology"},{"key":"4302_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. Lancet. 2008;371:660\u2013667.","journal-title":"Lancet"},{"key":"4302_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","volume":"30","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30:210\u2013226.","journal-title":"Aliment Pharmacol Ther"},{"key":"4302_CR24","first-page":"1293.e5","volume":"13","author":"MT Osterman","year":"2015","unstructured":"Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-TNF therapy in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13:1293.e5\u20131301.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4302_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/MIB.0b013e3182802909","volume":"19","author":"A Armuzzi","year":"2013","unstructured":"Armuzzi A, Pugliese D, Danese S, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065\u20131072.","journal-title":"Inflamm Bowel Dis"},{"key":"4302_CR26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, Noman M, Van Assche G, Baert F, D\u2019Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease. Gut. 2007;56:1226\u20131231.","journal-title":"Gut"},{"key":"4302_CR27","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1097\/MIB.0000000000000208","volume":"20","author":"T van Schaik","year":"2014","unstructured":"van Schaik T, Maljaars JPW, Roopram RK, et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis. 2014;20:2292\u20132298.","journal-title":"Inflamm Bowel Dis"},{"key":"4302_CR28","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","volume":"10","author":"C Ha","year":"2012","unstructured":"Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10:1002\u20131007. quiz e78.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4302-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-016-4302-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4302-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:35:27Z","timestamp":1589726127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-016-4302-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,17]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["4302"],"URL":"https:\/\/doi.org\/10.1007\/s10620-016-4302-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2016,9,17]]},"assertion":[{"value":"1 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no other financial relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}